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Background: Symetis SA, a Swiss company developing innovative transcatheter aortic valve implantation (TAVI) systems has completed enrollment 
(n=90) in two clinical studies of its ACURATE TA™ Aortic Bioprosthesis and Delivery System - the largest number of patients ever treated with a 2nd 
Generation TAVI device. The company has received a CE Mark and is already marketing this transapical TAVI system in Europe.
Methods: The studies were conducted at 6 sites in Germany and 90 high-risk patients with severe aortic stenosis were treated with the ACURATE 
TA™. The average age of patients is 83.5 ± 4.1 years, 69% are female, with a mean Logistic EuroScore of 20.4 ± 8.7% and STS Score of 8.4 ± 6.4%. 
Also, procedure success of 94.4% (n=85) is shown with 2 valve-in-valve and 3 conversions to open surgery.
Results: At 30 days, the ACURATE TA™ demonstrates a strong safety profile with 92.2% survival, a stroke and MI rate of 3.3% and 2.2%, respectively, 
and no further interventions were preformed on the implanted ACURATE TA™. Paravalvular leak of 0 - 1 occurred in 96.6% of followed patients. 
There were no patients with a leak greater than 2. Functional improvement from baseline was demonstrated in 84.0% of cases with NYHA Class I/II. 
Implantation of new pacemaker was required in 11.1% of cases.
Conclusion: These early data already confirm that ACURATE TA™ is a safe alternative to currently marketed TAVI devices. The midterm, or 6 months 
results, will be available for presentation by March 2012. Symetis is currently enrolling patients (n=250) in a post market surveillance registry for 
continued safety monitoring of the ACURATE TA™. The company also expects to start a FIM study of its transfemoral system, ACURATE TF™, by year’s 
end.
